VEGF pathway-targeted therapy for advanced renal cell carcinoma: A meta-analysis of randomized controlled trials

Abstract

Immunotherapy which has been in practice for more than 20 years proves effective for the treatment of metastatic renal cell carcinoma (mRCC). Anti-angiogenesis-targeted therapy has recently been identified as a promising therapeutic strategy for mRCC. This study was aimed to evaluate the effectiveness of vascular endothelial growth factor (VEGF) pathway-targeted therapy for mRCC by comparing its effectiveness with that of immunotherapy. The electronic databases were searched. Randomized controlled trials (RCTs) on comparison of VEGF inhibiting drugs (sorafenib, sunitinib and bevacizumab) with interferon (IFN) or placebo for mRCC treatment were included. Data were pooled to meta-analyze. A total of 7 RCTs with 3451 patients were involved. The results showed that anti-VEGF agents improved progression-free survival (PFS) and offered substantial clinical benefits to patients with mRCC. Among them, sunitinib had a higher overall response rate (ORR) than IFN (47% versus 12%, P<0.000001). Bevacizumab plus IFN produced a superior PFS [risk ratio (RR): 0.86, 95% confidence interval (CI): 0.76–0.97; P=0.01] and ORR (RR: 2.19; 95% CI: 1.72–2.78; P<0.00001) in patients with mRCC over IFN, but it yielded an increase by 31% in the risk of serious toxic effects (RR: 1.31; 95% CI: 1.20–1.43; P<0.00001) as compared with IFN. The overall survival (OS) was extended by sorafenib (17.8 months) and sunitinib (26.4 months) as compared with IFN (13 months). It was concluded that compared with IFN therapy, VEGF pathway-targeted therapies improved PFS and achieved significant therapeutic benefits in mRCC. However, the risk to benefit ratio of these agents needs to be further evaluated.

Keywords

renal cell carcinoma / targeted therapy / vascular endothelial growth factor / meta-analysis / immunotherapy

References

[1] JemalA., SiegelR., XuJ., et al.. Cancer statistics, 2010. CA Cancer J Clin, 2010, 60(5): 277-300

[2] KovacsG., AkhtarM., BeckwithB.J., et al.. The Heidelberg classification of renal cell tumours. J Pathol, 1997, 183(2): 131-133

[3] KarumanchiS.A., MerchanJ., SukhatmeV.P.. Renal cancer: molecular mechanisms and newer therapeutic options. Curr Opin Nephrol Hypertens, 2002, 11(1): 37-42

[4] JemalA., SiegelR., WardE., et al.. Cancer statistics, 2008. CA Cancer J Clin, 2008, 58(2): 71-96

[5] JemalA., SiegelR., WardE., et al.. Cancer statistics, 2009. CA Cancer J Clin, 2009, 59(4): 225-249

[6] LjungbergB., CowanN.C., HanburyD.C., et al.. EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol, 2010, 58(3): 398-406

[7] RouviereO., BouvierR., NegrierS., et al.. Nonmetastatic renal-cell carcinoma: is it really possible to define rational guidelines for post-treatment follow-up. Nat Clin Pract Oncol, 2006, 3(4): 200-213

[8] MotzerR.J., BanderN.H., NanusD.M.. Renal-cell carcinoma. N Engl J Med, 1996, 335(12): 865-875

[9] AmatoR.J.. Renal cell carcinoma: review of novel single-agent therapeutics and combination regimens. Ann Oncol, 2005, 16(1): 7-15

[10] LinehanW.M., ZbarB.. Focus on kidney cancer. Cancer Cell, 2004, 6(3): 223-228

[11] Medical Research Council Renal Cancer Collaborators.. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet, 1999, 353(9146): 14-17

[12] MotzerR.J., BacikJ., MurphyB.A., et al.. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol, 2002, 20(1): 289-296

[13] MotzerR.J., MurphyB.A., BacikJ., et al.. Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol, 2000, 18(16): 2972-2980

[14] GnarraJ.R., ToryK., WengY., et al.. Mutations of the VHL tumor suppressor gene in renal carcinoma. Nat Genet, 1994, 7(1): 85-90

[15] WiesenerM.S., MunchenhagenP.M., BergerI., et al.. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas. Cancer Res, 2001, 61(13): 5215-5222

[16] RiniB.I., SmallE.J.. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol, 2005, 23(5): 1028-1043

[17] DvorakH.F.. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol, 2002, 20(21): 4368-4380

[18] EscudierB., EisenT., StadlerW.M., et al.. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med, 2007, 356(2): 125-134

[19] MotzerR.J., HutsonT.E., TomczakP., et al.. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med, 2007, 356(2): 115-124

[20] YangJ.C., HaworthL., SherryR.M., et al.. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med, 2003, 349(5): 427-434

[21] SzczylikC.D., DemkowT., StaehlerM., et al.. Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: Final results. J Clin Oncol (Meeting Abstracts), 2007, 25: 5025

[22] JadadA.R., MooreR.A., CarrollD., et al.. Assessing the quality of reports of randomized clinical trials: is blinding necessary. Control Clin Trials, 1996, 17(1): 1-12

[23] AtkinsD., BrissP.A., EcclesM., et al.. Systems for grading the quality of evidence and the strength of recommendations II: pilot study of a new system. BMC Health Serv Res, 2005, 5(1): 25

[24] RatainM.J., EisenT., StadlerW.M., et al.. PhaseII placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol, 2006, 24(16): 2505-2512

[25] EscudierB., SzczylikC., HutsonT.E., et al.. Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol, 2009, 27(8): 1280-1289

[26] RiniB.I., HalabiS., RosenbergJ.E., et al.. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol, 2008, 26(33): 5422-5428

[27] EscudierB., PluzanskaA., KoralewskiP., et al.. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet, 2007, 370(9605): 2103-2111

[28] TherasseP., ArbuckS.G., EisenhauerE.A., et al.. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst, 2000, 92(3): 205-216

[29] FiglinR.A., HutsonT.E., TomczakP., et al.. Overall survival with sunitinib versus interferon (IFN)-alpha as first-line treatment of metastatic renal cell carcinoma (mRCC). J Clin Oncol (Meeting Abstracts), 2008, 26: 5024

[30] EscudierB., EisenT., StadlerW.M., et al.. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol, 2009, 27(20): 3312-3318

[31] National Cancer Institute. Common terminology criteria for adverse events (version 3). 2003. http://ctep.cancer. gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf.(accessed Mar 16, 2009).

[32] YangJ.C.. Bevacizumab for patients with metastatic renal cancer: an update. Clin Cancer Res, 2004, 10(18): 6367S-6370S

[33] RiniB.I.. Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions. Clin Cancer Res, 2007, 13(4): 1098-1106

[34] WilhelmS.M., CarterC., TangL., et al.. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res, 2004, 64(19): 7099-7109

[35] KaneR.C., FarrellA.T., SaberH., et al.. Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res, 2006, 12(24): 7271-7278

[36] MendelD.B., LairdA.D., XinX., et al.. In vivo anti-tumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res, 2003, 9(1): 327-337

[37] MotzerR.J., RiniB.I., BukowskiR.M., et al.. Sunitinib in patients with metastatic renal cell carcinoma. JAMA, 2006, 295(21): 2516-2524

[38] MotzerR.J., MichaelsonM.D., RedmanB.G., et al.. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol, 2006, 24(1): 16-24

[39] CoppinC., PorzsoltF., AwaA., et al.. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev, 2005, 25(1): CD001425

[40] NCCN. NCCN Clinical Practice Guidelines in OncologyTM. Kidney Cancer Version 2. 2009. http://www.nccn.org/professionals/physician_gls/PDF/kidney.pdf (accessed Mar 16, 2009).

[41] PrestaL.G., ChenH., O’ConnorS.J., et al.. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res, 1997, 57(20): 4593-4599

[42] BukowskiR.M., KabbinavarF.F., FiglinR.A., et al.. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol, 2007, 25(29): 4536-4541

[43] RiniB.I., CampbellS.C., EscudierB.. Renal cell carcinoma. Lancet, 2009, 373(9669): 1119-1132